Astellas Pharma Inc., founded in 2005 and headquartered in Tokyo, Japan, is a leading global pharmaceutical company dedicated to improving the health of patients through innovative medicines. The company specializes in a range of therapeutic areas, including urology, oncology, immunology, and neuroscience, with key products such as Xtandi, a treatment for prostate cancer, and Betanis for overactive bladder.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| YAMANO 0.26% 2025-12-05 JPYAstellas Pharma Inc. | Japan | 2025-12-05 | 0.260 | 0.72 |
| YAMANO 0.32% 2026-08-31 JPYAstellas Pharma Inc. | Japan | 2026-08-31 | 0.320 | 0.94 |
| YAMANO 0.42% 2027-12-03 JPYAstellas Pharma Inc. | Japan | 2027-12-03 | 0.419 | 1.19 |
| YAMANO 0.52% 2028-08-31 JPYAstellas Pharma Inc. | Japan | 2028-08-31 | 0.519 | 1.29 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Astellas has been active in the bond market for several years, first issuing bonds in 2007 to finance its growth and acquisitions. Notably, in 2020, Astellas issued a significant €1.25 billion bond to fund its acquisition of Xyphos Biosciences, showcasing its strategy to bolster its oncology portfolio. Current bond yields for Astellas are competitive within the pharmaceutical sector, reflecting strong credit quality, and the company continues to explore innovative financing strategies, including green bonds, to align with its sustainability goals.